Personalized stimulation to improve walking
- Trial ID
- NCT06350617
- Official Title
- Safety and Efficacy of Personalized Repetitive Transcranial Magnetic Stimulation Protocol Based on Functional Reserve to Enhance Ambulatory Function in Patients With Parkinson Disease
- Goal
- Personalized stimulation to improve walking
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Samsung Medical Center
- Study Type
- INTERVENTIONAL
- Enrollment
- 60 participants
- Conditions
- Parkinson's Disease and Parkinsonism
- Interventions
- High-Frequency, ipsilateral M1, High-Frequency, bilateral M1, High-Frequency, Lt. DLPFC, High-Frequency, bilateral M1
Plain-Language Summary
The goal is to help people with Parkinson's walk better by boosting the brain networks that support gait and balance. The approach uses personalized, high-frequency repetitive transcranial magnetic stimulation, targeting the motor cortex (one side or both) and sometimes the left dorsolateral prefrontal cortex, with the protocol tuned to each person’s functional reserve so the most responsive brain areas get stronger magnetic pulses; the pulses increase excitability in those circuits, they are noninvasive, and they do not replace levodopa but may make motor circuits more responsive to medications. The trial is looking for adults aged 50 and up with Parkinson’s (UK Brain Bank criteria) in Hoehn and Yahr stages 2 to 4 who can walk on flat ground without a gait aid. People with epilepsy or metal in the head, significant cognitive impairment by MoCA thresholds, other major neurological or psychiatric disorders, severe on-off swings or dyskinesia, MRI contraindications, or pregnancy are excluded.
Locations
- Samsung Medical Center, Seoul, South Korea
Frequently Asked Questions
- What is this trial testing?
- This trial is studying High-Frequency, ipsilateral M1. The goal is to help people with Parkinson's walk better by boosting the brain networks that support gait and balance. The approach uses personalized, high-frequency repetitive transcranial magnetic stimulation, targeting the motor cortex (one side or both) and sometimes the left dorsolateral prefrontal cortex, with the protocol tuned to each person’s functional reserve so the most responsive brain areas get stronger magnetic pulses; the pulses increase excitability in those circuits, they are noninvasive, and they do not replace levodopa but may make motor circuits more responsive to medications. The trial is looking for adults aged 50 and up with Parkinson’s (UK Brain Bank criteria) in Hoehn and Yahr stages 2 to 4 who can walk on flat ground without a gait aid. People with epilepsy or metal in the head, significant cognitive impairment by MoCA thresholds, other major neurological or psychiatric disorders, severe on-off swings or dyskinesia, MRI contraindications, or pregnancy are excluded.
- Who can participate?
- Participants must be at least 50 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 7 months.